Cabaletta Bio

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART, is bbe

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART, is b

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART, is

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART, iis

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART, i

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART,

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART,

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAARDSG3-CAART

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAADSG3-CAAR

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CADSG3-CAA

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CDSG3-CA

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3-DSG3-C

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSG3DSG3-

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSGDSG3

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DSDSG

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, DDS

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate, D

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate,

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidate,

On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patientss with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABATM) platform is focused on eliminating pathogenic B cells that express autoantibodies,, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABATM platform may provide a biological opportunity for cure. Our lead candidatcandidate